Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ROIV
ROIV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ROIV News
Moderna Surpasses Q1 Revenue Estimates Driven by International Vaccine Sales
May 01 2026
Newsfilter
Roivant Sciences (ROIV.US) Officer Plans to Sell $8.45 Million in Common Stock via Form 144 Amendment
Apr 16 2026
moomoo
Priovant Launches Phase 2b/3 Trial for Lichen Planopilaris
Apr 02 2026
Newsfilter
Roivant Launches New Clinical Trial for LPP
Apr 02 2026
Newsfilter
S&P 500 Futures Rise in Pre-Market Session; United Therapeutics and Alcoa Take the Lead
Mar 30 2026
Barron's
Brepocitinib Shows Significant Benefits in Dermatomyositis Trial
Mar 28 2026
Newsfilter
ROIV Options Contract Analysis and Investment Opportunities
Mar 06 2026
NASDAQ.COM
BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares
Mar 05 2026
NASDAQ.COM
BlackBarn Capital Increases Warby Parker Stake to 3 Million Shares
Mar 05 2026
Fool
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Mar 04 2026
stocktwits
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
Mar 04 2026
Benzinga
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
Mar 03 2026
stocktwits
Moderna Settles for $2.25 Billion with Genevant and Arbutus Over Patent Infringement
Mar 03 2026
Globenewswire
Moderna Settles $2.25 Billion Patent Dispute with Genevant and Arbutus
Mar 03 2026
Newsfilter
Priovant Secures FDA Priority Review for Brepocitinib
Mar 03 2026
seekingalpha
Priovant's Dermatomyositis Drug Receives FDA Priority Review
Mar 03 2026
Newsfilter
Show More News
